Molecular mechanisms of progression in human hepatocarcinogenesis;Molekulare Progressionsmechanismen der humanen Hepatokarzinogenese

Pathologe

Volumn 31, Issue SUPPL. 2, 2010, Pages 170-176

  Breuhahn, K ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Growth factors; Inhibition; Insulin like growth factor 1 receptor; Insulin like growth factor II; Tyrosine kinases

Indexed keywords

IGF2 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER TRANSPLANTATION; CELL DIVISION; CELL TRANSFORMATION; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; NEOPLASM TRANSPLANTATION; PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 79953218805     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-010-1337-7     Document Type: Article

References (27)

1. Bardelli A, Longati P, Gramaglia D et al (1997) Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 15:3103-3111
2. Bauer TW, Liu W, Fan F et al (2005) Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65:7775-7781
3. Bauer TW, Somcio RJ, Fan F et al (2006) Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 5:1676-1682
4. Boissan M, Beurel E, Wendum D et al (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167:869-877
5. Boyault S, Rickman DS, De Reynies A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42-52
6. Breuhahn K, Longerich T, Schirmacher P (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25:3787-3800
7. Breuhahn K, Schirmacher P (2008) Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol 14:1690-1698
8. Breuhahn K, Vreden S, Haddad R et al (2004) Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64:6058-6064
9. Cantarini MC, De La Monte SM, Pang M et al (2006) Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 44:446-457
10. Dong ZZ, Yao DF, Yao DB et al (2005) Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 11:4655-4660
11. El-Serag HB, Rudolph Kl (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576
12. Girnita A, Girnita L, Del Prete F et al (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64:236-242
13. Guirouilh J, Castroviejo M, Balabaud C et al (2000) Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int J Oncol 17:777-781
14. Haddad R, Held WA (1997) Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res 57:4615-4623
15. Hopfner M, Huether A, Sutter AP et al (2006) Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 71:1435-1448
16. Li X, Nong Z, Ekstrom C et al (1997) Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 57:2048-2054
17. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
18. Lund P, Schubert D, Niketeghad F et al (2004) Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 206:85-96
19. Menu E, Jernberg-Wiklund H, Stromberg T et al (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107:655-660
20. Nussbaum T, Samarin J, Ehemann V et al (2008) Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 48:146-156
21. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
22. Rosengren L, Vasilcanu D, Vasilcanu R et al (2006) IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem Biophys Res Commun 347:1059-1066
23. Schirmacher P, Held WA, Yang D et al (1992) Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 52:2549-2556
24. Sciacca L, Costantino A, Pandini G et al (1999) Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18:2471-2479
25. Sohda T, Oka Y, Iwata K et al (1997) Co-localisation of insulin-like growth factor II and the proliferation marker MIB1 in hepatocellular carcinoma cells. J Clin Pathol 50:135-137
26. Vu TH, Hoffman AR (1994) Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature 371:714-717
27. Zhong Wu X, Honke K, Long Zhang Y et al (2004) Lactosylsulfatide expression in hepatocellular carcinoma cells enhances cell adhesion to vitronectin and intrahepatic metastasis in nude mice. Int J Cancer 110:504-510